869357-63-1

Basic information

• Product Name: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate
• Synonyms: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate;Methyl 5-bromo-2-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 869357-63-1
• Molecular Formula: C8H7BrClNO3
• Molecular Weight: 280.50308
• EINECS: -0
• Mol File: 869357-63-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(869357-63-1)
• EPA Substance Registry System: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(869357-63-1)

Safety Data

• Hazardous Substances Data: 869357-63-1(Hazardous Substances Data)

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 38025-90-0 2-chloro-6-oxo-1,6-dihydropyridine-3-carboxylic acid 
• 853109-24-7 methyl 2-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 

Downstream Products

• 869357-67-5 2-(2-fluoro-4-iodo-anilino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester 
• 869357-68-6 2-[(2-fluoro-4-iodoiodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide 
• 934639-06-2 2-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridine-3-carboxamide 

Relevant articles and documents

Aryl spiro SHP2 inhibitor compound as well as preparation method and application thereof

The invention discloses an aryl spiro SHP2 inhibitor compound as well as a preparation method and application thereof. The invention particularly relates to a nitrogen-containing aryl spiro compound shown as a general formula I (See the specification), or pharmaceutically acceptable salt thereof, or an enantiomer, diastereoisomer, tautomer, solvate, polymorphic substance or prodrug thereof, a preparation method thereof and application thereof in pharmacy, and the definition of each group is shown in the specification.

DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS

This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N'-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.

COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with AZD6244 or MEK Inhibitor II; to a pharmaceutical composition comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to a combination product comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to the use of AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER

This invention relates to a combination product comprising a MEK inhibitor and a B-raf inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a combination product comprising a MEK inhibitor and a B raf inhibitor; a combination product comprising a kit of parts comprising a MEK inhibitor and a B-raf inhibitor; use of the combination product in the treatment of cancer; a method of treating cancer comprising administering the combination product to a patient. The combination product and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or B-raf.

HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF

Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Heterocyclic inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.